| Jiaming Li,Sujiang Zhang,Yubao Chen,Zeying Yan,Ying Wang,Zhiyin Liu,Haimin Sun,Yu Chen. Efficacy and safety of combined decitabine and ruxolitinib in the treatment of chronic myelomonocytic leukemia. Oncol Transl Med, 2019, 5: 237-241. |
| Efficacy and safety of combined decitabine and ruxolitinib in the treatment of chronic myelomonocytic leukemia |
| Received:April 08, 2019 Revised:November 14, 2019 |
| View Full Text View/Add Comment Download reader |
| KeyWord:decitabine (DEC); ruxolitinib (RUX); chronic myelomonocytic leukemia (CMML) |
| Author Name | Affiliation | E-mail | | Jiaming Li | Ruijin Hospital North Affiliated with Shanghai Jiao Tong University School of Medicine | lijiaming007007@126.com | | Sujiang Zhang | Ruijin Hospital North Affiliated with Shanghai Jiao Tong University School of Medicine | zhangsjb1181@126.com | | Yubao Chen | Ruijin Hospital North Affiliated with Shanghai Jiao Tong University School of Medicine | | | Zeying Yan | Ruijin Hospital North Affiliated with Shanghai Jiao Tong University School of Medicine | | | Ying Wang | Ruijin Hospital North Affiliated with Shanghai Jiao Tong University School of Medicine | | | Zhiyin Liu | Ruijin Hospital North Affiliated with Shanghai Jiao Tong University School of Medicine | | | Haimin Sun | Ruijin Hospital North Affiliated with Shanghai Jiao Tong University School of Medicine | | | Yu Chen | Ruijin Hospital North Affiliated with Shanghai Jiao Tong University School of Medicine | |
|
| Hits: 5829 |
| Download times: 6651 |
| Abstract: |
| Objective The aim of the study was to evaluate the clinical efficacy of decitabine (DEC) combined with
ruxolitinib (RUX) in the treatment of chronic myelomonocytic leukemia (CMML).
Methods The clinical characteristics of 12 patients with CMML were analyzed retrospectively and
subsequent target sequencing was performed to investigate the efficacy of the combined treatment with
DEC and RUX and the molecular signatures therein.
Results Among the 12 cases, clinical improvement was observed in all patients (100%), spleen reduction
was observed in six patients (67%), and hematologic improvement was observed in four patients (33%).
In the CMML-1 group, the overall response was 50% (3/6), one case achieved complete response, one
achieved bone marrow remission, and one achieved hematological improvement. In the CMML-2 group, the
overall response was 17% (1/6), one case achieved complete response, four showed disease progression
(PD), and one exhibited no response. As expected, ASXL1 mutation was predictive for the outcome of
CMML (hazard ratio of 2.97, 95% confidence interval of 1.21–7.06; P = 0.02).
Conclusion The use of DEC combined with RUX in the treatment of CMML effectively improved the
clinical response and quality of life, especially for CMML-1 patients. Ongoing clinical trials will further
evaluate the safety and efficacy of this novel therapeutic approach. |
| Close |
|
|
|